Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 93
Filtrar
1.
Mol Oncol ; 17(7): 1343-1355, 2023 07.
Artigo em Inglês | MEDLINE | ID: mdl-36808802

RESUMO

Parathyroid carcinoma (PC) is an ultra-rare malignancy with a high risk of recurrence after surgery. Tumour-directed systemic treatments for PC are not established. We used whole-genome and RNA sequencing in four patients with advanced PC to identify molecular alterations that could guide clinical management. In two cases, the genomic and transcriptomic profiles provided targets for experimental therapies that resulted in biochemical response and prolonged disease stabilization: (a) immune checkpoint inhibition with pembrolizumab based on high tumour mutational burden and a single-base substitution signature associated with APOBEC (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like) overactivation; (b) multi-receptor tyrosine kinase inhibition with lenvatinib due to overexpression of FGFR1 (Fibroblast Growth Factor Receptor 1) and RET (Ret Proto-Oncogene) and, (c) later in the course of the disease, PARP (Poly(ADP-Ribose) Polymerase) inhibition with olaparib prompted by signs of defective homologous recombination DNA repair. In addition, our data provided new insights into the molecular landscape of PC with respect to the genome-wide footprints of specific mutational processes and pathogenic germline alterations. These data underscore the potential of comprehensive molecular analyses to improve care for patients with ultra-rare cancers based on insight into disease biology.


Assuntos
Carcinoma , Neoplasias das Paratireoides , Humanos , Neoplasias das Paratireoides/tratamento farmacológico , Neoplasias das Paratireoides/genética , Neoplasias das Paratireoides/patologia , Transcriptoma/genética , Mutação/genética , Genômica/métodos , Perfilação da Expressão Gênica/métodos , Carcinoma/genética
2.
Intern Med ; 61(22): 3383-3390, 2022 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-35370235

RESUMO

Parathyroid carcinoma (PC) is a rare type of endocrine cancer. Recurrence and metastasis are common after surgery, and refractory hypercalcemia often leads to a poor prognosis. However, there are currently no specific strategies for PC recurrence. We herein report a 61-year-old Japanese man with metastatic PC who was treated with sorafenib, a multikinase inhibitor. In this case, the serum calcium level was under control for 10 months after the initiation of sorafenib. This case suggests that combination therapy with sorafenib, evocalcet, and denosumab may be an alternative, stronger management option for refractory hypercalcemia in recurrent PC.


Assuntos
Hipercalcemia , Neoplasias das Paratireoides , Masculino , Humanos , Pessoa de Meia-Idade , Neoplasias das Paratireoides/complicações , Neoplasias das Paratireoides/tratamento farmacológico , Neoplasias das Paratireoides/cirurgia , Hipercalcemia/tratamento farmacológico , Hipercalcemia/etiologia , Denosumab/uso terapêutico , Sorafenibe/uso terapêutico , Recidiva Local de Neoplasia/patologia , Hormônio Paratireóideo
3.
J Bone Miner Metab ; 39(4): 583-588, 2021 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-33409573

RESUMO

INTRODUCTION: Cinacalcet is a calcimimetic that modulates the functions of calcium-sensing receptor and is currently used to treat patients with primary hyperparathyroidism (PHPT). Although it was reported that cinacalcet treatment reduced the size of hyperplastic parathyroid glands in patients with secondary hyperparathyroidism, whether or not cinacalcet treatment can reduce the size of parathyroid adenomas in patients with PHPT has been unknown. MATERIALS AND METHODS: We recruited nine (male: one, female: eight) patients with PHPT due to parathyroid adenomas who did not undergo parathyroidectomy. Cinacalcet was administered at a dose of 50 mg/day, and we evaluated the size of parathyroid adenomas (width × thickness) (mm2) using ultrasonography before and after 6 months of cinacalcet treatment. RESULTS: The mean age of the subjects was 58.1 ± 7.2 years old, and the mean serum intact parathyroid hormone (PTH) concentration was 134.8 ± 8.7 pg/ml. All participants showed hypercalcemia and osteopenia. After 6 months, the mean size of parathyroid adenomas was significantly decreased (baseline: 73.8 ± 33.4 mm2 vs. after 6 months: 52.5 ± 25.0 mm2, p = 0.045). Thus, 6-month cinacalcet treatment induced a 29% size reduction in parathyroid adenomas. Furthermore, the serum intact PTH concentration before cinacalcet treatment was positively correlated with the reduction in the size of parathyroid adenomas. CONCLUSION: The present study revealed that cinacalcet treatment reduces the size of parathyroid adenomas in patients with PHPT. The accumulation of more PHPT cases with cinacalcet therapy is required to confirm this finding.


Assuntos
Adenoma/complicações , Adenoma/tratamento farmacológico , Cinacalcete/uso terapêutico , Hiperparatireoidismo Primário/complicações , Neoplasias das Paratireoides/complicações , Neoplasias das Paratireoides/tratamento farmacológico , Adenoma/sangue , Adenoma/diagnóstico por imagem , Cálcio/sangue , Cinacalcete/efeitos adversos , Feminino , Humanos , Hiperparatireoidismo Primário/sangue , Hiperparatireoidismo Primário/diagnóstico por imagem , Masculino , Pessoa de Meia-Idade , Hormônio Paratireóideo/sangue , Neoplasias das Paratireoides/sangue , Neoplasias das Paratireoides/diagnóstico por imagem , Paratireoidectomia , Carga Tumoral , Ultrassonografia
4.
J Coll Physicians Surg Pak ; 30(7): 757-759, 2020 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-32811610

RESUMO

Parathyroid carcinoma is a rare cause of hyperparathyroidism and leads to severe hypercalcemia. The etiology is not fully known. Parathyroid cancer should be considered in the differential diagnosis, if serum calcium and parathyroid hormone levels increase, and parathyroid gland is palpable. Severe hypercalcemia is the most common cause of death in patients diagnosed with parathyroid carcinoma. Fluid replacement, diuretic therapy, bisphosphonates, and calcimimetic agents are the main treatment steps in the control of life-threatening hypercalcemia. Surgery is the primary treatment option, while denosumab is a treatment option for refractory hypercalcemia caused by parathyroid carcinoma, or for patients who are not eligible for surgery. There are few case reports in literature about denosumab treatment for parathyroid carcinoma. Herein, we report a case of a patient who presented with the complaint of leg pain and was diagnosed with parathyroid carcinoma. The elevated calcium level of the patient was controlled with denosumab. Key Words: Parathyroid carcinoma, Denosumab, Hypercalcemia, Hyperparathyroidism.


Assuntos
Conservadores da Densidade Óssea , Denosumab , Hipercalcemia , Neoplasias das Paratireoides , Conservadores da Densidade Óssea/uso terapêutico , Denosumab/uso terapêutico , Difosfonatos , Humanos , Hipercalcemia/tratamento farmacológico , Hipercalcemia/etiologia , Hormônio Paratireóideo , Neoplasias das Paratireoides/complicações , Neoplasias das Paratireoides/tratamento farmacológico , Neoplasias das Paratireoides/cirurgia
5.
Eur J Endocrinol ; 181(3): P1-P19, 2019 09 01.
Artigo em Inglês | MEDLINE | ID: mdl-31176307

RESUMO

PARAT, a new European Society of Endocrinology program, aims to identify unmet scientific and educational needs of parathyroid disorders, such as primary hyperparathyroidism (PHPT), including parathyroid cancer (PC), and hypoparathyroidism (HypoPT). The discussions and consensus statements from the first PARAT workshop (September 2018) are reviewed. PHPT has a high prevalence in Western communities, PHPT has a high prevalence in Western communities, yet evidence is sparse concerning the natural history and whether morbidity and long-term outcomes are related to hypercalcemia or plasma PTH concentrations, or both. Cardiovascular mortality and prevalence of low energy fractures are increased, whereas Quality of Life is decreased, although their reversibility by treatment of PHPT has not been convincingly demonstrated. PC is a rare cause of PHPT, with an increasing incidence, and international collaborative studies are required to advance knowledge of the genetic mechanisms, biomarkers for disease activity, and optimal treatments. For example, ~20% of PCs demonstrate high mutational burden, and identifying targetable DNA variations, gene amplifications and gene fusions may facilitate personalized care, such as different forms of immunotherapy or targeted therapy. HypoPT, a designated orphan disease, is associated with a high risk of symptoms and complications. Most cases are secondary to neck surgery. However, there is a need to better understand the relation between disease biomarkers and intellectual function, and to establish the role of PTH in target tissues, as these may facilitate the appropriate use of PTH substitution therapy. Management of parathyroid disorders is challenging, and PARAT has highlighted the need for international transdisciplinary scientific and educational studies in advancing in this field.


Assuntos
Educação/métodos , Endocrinologia/educação , Endocrinologia/métodos , Doenças das Paratireoides/tratamento farmacológico , Sociedades Médicas , Europa (Continente)/epidemiologia , Humanos , Hiperparatireoidismo Primário/diagnóstico , Hiperparatireoidismo Primário/tratamento farmacológico , Hiperparatireoidismo Primário/metabolismo , Doenças das Paratireoides/diagnóstico , Doenças das Paratireoides/metabolismo , Hormônio Paratireóideo/uso terapêutico , Neoplasias das Paratireoides/diagnóstico , Neoplasias das Paratireoides/tratamento farmacológico , Neoplasias das Paratireoides/metabolismo
6.
Oncologist ; 24(6): 791-797, 2019 06.
Artigo em Inglês | MEDLINE | ID: mdl-30373905

RESUMO

BACKGROUND: Parathyroid carcinoma (PC) is a rare endocrine malignancy that can cause life-threatening hypercalcemia. We queried whether comprehensive genomic profiling (CGP) of PC might identify genomic alterations (GAs), which would suggest benefit from rationally matched therapeutics. METHODS: We performed hybrid-capture-based CGP to identify GAs and tumor mutational burden (TMB) in tumors from patients with this malignancy. RESULTS: There were 85 total GAs in 16 cases (5.3 GAs per case), and the median TMB was 1.7 mutations per megabase (m/Mb), with three cases having >20 m/Mb (18.7%). The genes most frequently harboring GA were CDC73 (38%), TP53 (38%), and MEN1 (31%). All MEN1-mutated cases also had loss of heterozygosity at that locus, but in contrast all CDC73-mutated cases retained heterozygosity. GAs suggesting potential benefit from matched targeted therapy were identified in 11 patients (69%) and most frequently found in PTEN (25%), NF1 (12.5%), KDR (12.5%), PIK3CA (12.5%), and TSC2 (12.5%). A patient whose tumor harbored KDR T668 K and who was treated with cabozantinib experienced a > 50% drop in parathyroid hormone level and radiographic partial response of 5.4 months with duration limited by toxicity. CONCLUSION: CGP identified GAs in PC that suggest benefit from targeted therapy, as supported by an index case of response to a matched tyrosine kinase inhibitor. Moreover, the unexpectedly high frequency of high TMB (>20 m/Mb) suggests a subset of PC may benefit from immune checkpoint inhibitors. IMPLICATIONS FOR PRACTICE: Parathyroid carcinoma (PC) is a rare endocrine malignancy that can cause life-threatening hypercalcemia. However, its molecular characteristics remain unclear, with few systemic therapeutic options available for this tumor. Hybrid-capture-based comprehensive genomic profiling of 16 primary cancers demonstrated presence of potentially actionable genomic alterations, including PTEN, NF1, KDR, PIK3CA, and TSC2, and a subset of hypermutated cancers with more than 20 mutations per megabase, the latter of which could benefit from immune checkpoint inhibitor therapy. A case benefiting from rationally matched targeted therapy for activating KDR mutation is also presented. These findings should be further investigated for their therapeutic potential.


Assuntos
Antineoplásicos/uso terapêutico , Biomarcadores Tumorais/genética , Perfilação da Expressão Gênica , Neoplasias das Paratireoides/tratamento farmacológico , Medicina de Precisão/métodos , Adulto , Idoso , Antineoplásicos/farmacologia , Biomarcadores Tumorais/antagonistas & inibidores , Estudos de Coortes , Feminino , Genômica/métodos , Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Masculino , Pessoa de Meia-Idade , Terapia de Alvo Molecular/métodos , Taxa de Mutação , Neoplasias das Paratireoides/genética , Seleção de Pacientes
7.
Endocr Relat Cancer ; 24(6): R239-R259, 2017 06.
Artigo em Inglês | MEDLINE | ID: mdl-28400402

RESUMO

Tumourigenesis is a relatively common event in endocrine tissues. Currently, specific guidelines have been developed for common malignant endocrine tumours, which also incorporate advances in molecular targeted therapies (MTT), as in thyroid cancer and in gastrointestinal neuroendocrine malignancies. However, there is little information regarding the role and efficacy of MTT in the relatively rare malignant endocrine tumours mainly involving the adrenal medulla, adrenal cortex, pituitary, and parathyroid glands. Due to the rarity of these tumours and the lack of prospective studies, current guidelines are mostly based on retrospective data derived from surgical, locoregional and ablative therapies, and studies with systemic chemotherapy. In addition, in many of these malignancies the prognosis remains poor with individual patients responding differently to currently available treatments, necessitating the development of new personalised therapeutic strategies. Recently, major advances in the molecular understanding of endocrine tumours based on genomic, epigenomic, and transcriptome analysis have emerged, resulting in new insights into their pathogenesis and molecular pathology. This in turn has led to the use of novel MTTs in increasing numbers of patients. In this review, we aim to present currently existing and evolving data using MTT in the treatment of adrenal, pituitary and malignant parathyroid tumours, and explore the current utility and effectiveness of such therapies and their future evolution.


Assuntos
Neoplasias das Glândulas Suprarrenais/tratamento farmacológico , Neoplasias das Paratireoides/tratamento farmacológico , Neoplasias Hipofisárias/tratamento farmacológico , Neoplasias das Glândulas Suprarrenais/metabolismo , Animais , Humanos , Terapia de Alvo Molecular , Paraganglioma/tratamento farmacológico , Paraganglioma/metabolismo , Neoplasias das Paratireoides/metabolismo , Feocromocitoma/tratamento farmacológico , Feocromocitoma/metabolismo , Neoplasias Hipofisárias/metabolismo
8.
J Med Case Rep ; 11(1): 81, 2017 Mar 26.
Artigo em Inglês | MEDLINE | ID: mdl-28342443

RESUMO

BACKGROUND: Atypical carcinoid arising from the mediastinal tissue is a rare neuroendocrine tumor and an association with parathyroid adenoma is very unusual. We report an unusual case of atypical carcinoid of mediastinum with metastasis in a patient presenting with parathyroid adenoma, which is the first case to be reported from Pakistan. CASE PRESENTATION: A 51-year-old Pakistani man was seen in postoperative intensive care after right parathyroidectomy and mediastinal mass resection for the management of postoperative hypocalcaemia. He had a background history of dyspnea. Examination was unremarkable. Preoperative laboratory evaluation revealed a calcium level of 12.7 mg/dl, phosphate of 1.9 mg/dl, serum albumin of 4.8 g/dl, alkaline phosphate of 94 U/L, and serum intact parathyroid hormone level 413.8 pg/ml. A technetium-99m sestamibi parathyroid scan showed right parathyroid increased tracer uptake. Further workup revealed a large mediastinal mass which was diagnosed as atypical carcinoid after Tru-Cut biopsy. He underwent right-sided parathyroidectomy and resection of the mediastinal mass. The histopathology confirmed it to be a parathyroid adenoma and atypical carcinoid tumor of his mediastinum with metastasis in his lymph node and parathyroid gland. Somatostatin receptor scintigraphy revealed a well-defined focus in his left hypochondriac region consistent with a somatostatin receptor scintigraphy-avid tumor. He was started on everolimus and planned for octreotide therapy. CONCLUSIONS: We describe an incidental finding of atypical carcinoid of the mediastinum in a patient diagnosed as having parathyroid adenoma. Clinical manifestations of neuroendocrine syndromes are challenging. Some tumors cluster in a non-classic description with other common neoplasms. They rarely present in isolation, remain clinically silent, and need aggressive workup with the aid of imaging and histopathology.


Assuntos
Tumor Carcinoide/diagnóstico , Hipocalcemia/cirurgia , Neoplasias do Mediastino/diagnóstico , Mediastino/patologia , Neoplasias das Paratireoides/diagnóstico , Paratireoidectomia , Antineoplásicos/uso terapêutico , Tumor Carcinoide/tratamento farmacológico , Tumor Carcinoide/patologia , Everolimo/uso terapêutico , Humanos , Achados Incidentais , Masculino , Neoplasias do Mediastino/tratamento farmacológico , Neoplasias do Mediastino/patologia , Pessoa de Meia-Idade , Neoplasias das Paratireoides/tratamento farmacológico , Neoplasias das Paratireoides/patologia , Resultado do Tratamento
9.
J Bone Miner Metab ; 35(6): 616-622, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-27873072

RESUMO

Pharmacological treatment of hypercalcemia is essential for patients with parathyroid carcinoma and intractable primary hyperparathyroidism (PHPT). Use of the calcimimetic cinacalcet hydrochloride (cinacalcet) is an option to treat such patients. We investigated the efficacy and safety of cinacalcet in Japanese patients with parathyroid carcinoma and intractable PHPT. Five Japanese patients with parathyroid carcinoma and two with intractable PHPT were enrolled in an open-label, single-arm study consisting of titration and maintenance phases. Cinacalcet doses were titrated until the albumin-corrected serum calcium concentration decreased to 10.0 mg/dL or less or until dose escalation was considered not necessary or feasible. Serum calcium concentration at the baseline was 12.1 ± 1.3 mg/dL (mean ± standard deviation; range 10.4-14.6 mg/dL) and decreased to 10.1 ± 1.6 mg/dL (range 8.6-13.3 mg/dL) at the end of the titration phase with cinacalcet at a dosage of up to 75 mg three times a day. At the end of the titration phase, at least a 1 mg/dL reduction in serum calcium concentration from the baseline was observed in five patients (three with carcinoma and two with PHPT), and it decreased to the normocalcemic range in five patients (three with carcinoma and two with PHPT). Common adverse events were nausea and vomiting. One patient discontinued participation in the study because of an adverse event, liver disorder. Cinacalcet effectively relieved hypercalcemia in 60% of the Japanese patients with parathyroid carcinoma and might be effective in those with intractable PHPT. The drug might be tolerable and safe at a dosage of at most 75 mg three times a day.


Assuntos
Povo Asiático , Cinacalcete/uso terapêutico , Hipercalcemia/tratamento farmacológico , Hiperparatireoidismo Primário/complicações , Neoplasias das Paratireoides/complicações , Neoplasias das Paratireoides/tratamento farmacológico , Adulto , Idoso , Cálcio/sangue , Cálcio da Dieta/uso terapêutico , Cinacalcete/efeitos adversos , Cinacalcete/farmacologia , Creatinina/sangue , Demografia , Relação Dose-Resposta a Droga , Eletrocardiografia , Feminino , Humanos , Hipercalcemia/sangue , Hipercalcemia/diagnóstico por imagem , Hiperparatireoidismo Primário/sangue , Hiperparatireoidismo Primário/diagnóstico por imagem , Masculino , Pessoa de Meia-Idade , Hormônio Paratireóideo/sangue , Neoplasias das Paratireoides/sangue , Neoplasias das Paratireoides/diagnóstico por imagem , Fósforo/sangue , Sinais Vitais
10.
Endocrine ; 52(3): 495-506, 2016 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-26224587

RESUMO

Primary hyperparathyroidism is the main endocrinopathy associated with Multiple Endocrine Neoplasia type 1 syndrome. Cinacalcet is a calcimimetic agent licensed for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease, and for the reduction of marked hypercalcemia in patients with parathyroid carcinoma and sporadic hyperparathyroidism requiring surgery but for whom parathyroidectomy is contraindicated. It may provide a medical alternative for the management of primary hyperparathyroidism in subjects affected by Multiple Endocrine Neoplasia type 1. In this longitudinal, intervention study, 33 MEN1 patients had been enrolled, 10 males and 23 females with a mean age of 40 ± 11.9 years, range 20-63. Primary hyperparathyroidism was the first clinical manifestation in 12 patients. All subjects commenced with Cinacalcet 30 mg/day, 22 patients starting therapy with calcimimetics as an alternative to surgery, and 11 patients opting for the medication after the onset of persistent post-surgical primary hyperparathyroidism. Duration of follow-up was 12 months. The results of this study show significant reductions in serum calcium. The changes in hormonal secretions of pituitary and gastroenteropancreatic glands were not significant, demonstrating the overall safety of this drug in this disease. Cinacalcet has been well tolerated by 28 patients, whereas five individuals complained of heartburn and grade 1 nausea, which did not prevent the completion of the study. In conclusion, Cinacalcet has resulted to be well tolerated and safe in patients with MEN1 syndrome and the calcium homeostasis was stabilized.


Assuntos
Adenoma/tratamento farmacológico , Cinacalcete/uso terapêutico , Hiperparatireoidismo Primário/tratamento farmacológico , Neoplasia Endócrina Múltipla Tipo 1/tratamento farmacológico , Neoplasias das Paratireoides/tratamento farmacológico , Adenoma/sangue , Adenoma/complicações , Adenoma/metabolismo , Adulto , Cálcio/sangue , Feminino , Humanos , Hiperparatireoidismo Primário/sangue , Hiperparatireoidismo Primário/etiologia , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Neoplasia Endócrina Múltipla Tipo 1/sangue , Neoplasia Endócrina Múltipla Tipo 1/complicações , Hormônio Paratireóideo/sangue , Neoplasias das Paratireoides/sangue , Neoplasias das Paratireoides/complicações , Neoplasias das Paratireoides/metabolismo , Paratireoidectomia , Adulto Jovem
11.
Am J Otolaryngol ; 36(5): 701-3, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26026702

RESUMO

Parathyroidectomy is considered the definitive cure for primary hyperparathyroidism due to a single parathyroid adenoma, which represents the most common cause of chronic hypercalcemia. However, in few cases, surgery may be technically difficult or risky. We report the use of percutaneous ultrasound-guided alcohol ablation of a parathyroid adenoma as an alternative to surgery in an 88-year-old male patient with significant medical comorbidities.


Assuntos
Adenoma/tratamento farmacológico , Etanol/administração & dosagem , Hiperparatireoidismo Primário/etiologia , Neoplasias das Paratireoides/tratamento farmacológico , Adenoma/complicações , Adenoma/diagnóstico por imagem , Idoso de 80 Anos ou mais , Humanos , Injeções Intralesionais , Masculino , Neoplasias das Paratireoides/complicações , Neoplasias das Paratireoides/diagnóstico por imagem , Ultrassonografia
14.
Eur J Endocrinol ; 171(1): K1-5, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24743399

RESUMO

OBJECTIVE: Hypercalcaemia is an important cause of increased morbidity and mortality in patients with parathyroid carcinoma. Surgical resection is the mainstay of treatment but, equally, managing hypercalcaemia is of paramount importance. At present, few therapies have been shown to be effective in the most severe cases. This report describes the efficacy of denosumab in a patient with parathyroid carcinoma when conventional therapies had been shown to be relatively ineffective.SUBJECT, METHODS AND RESULTS: A 50-year-old man presented with symptomatic hypercalcaemia 1 year after the surgery for his parathyroid carcinoma. Investigations revealed raised serum calcium and parathyroid hormone concentrations consistent with the recurrence of the disease. Imaging failed to localise any surgically remediable foci. Medical management with loop diuretics, calcimimetics and bisphosphonates failed to provide a sustained response. Denosumab, as a monthly injection, led to a gradual decrement in his peak calcium concentrations with the values now persistently below 3 mmol/l. CONCLUSIONS: Denosumab, a fully human MAB that binds to the 'receptor activator of nuclear factor κB ligand (RANKL)', was shown to have a profound effect in modulating malignant hypercalcaemia. This medication should be considered as an effective option in patients with refractory hypercalcaemia secondary to parathyroid carcinoma.


Assuntos
Anticorpos Monoclonais Humanizados/uso terapêutico , Hipercalcemia/sangue , Hipercalcemia/tratamento farmacológico , Síndromes Paraneoplásicas/sangue , Síndromes Paraneoplásicas/tratamento farmacológico , Neoplasias das Paratireoides/sangue , Neoplasias das Paratireoides/tratamento farmacológico , Cálcio/sangue , Denosumab , Humanos , Masculino , Pessoa de Meia-Idade , Hormônio Paratireóideo/sangue
15.
Orphanet J Rare Dis ; 8: 115, 2013 Aug 03.
Artigo em Inglês | MEDLINE | ID: mdl-23915575

RESUMO

Parathyroid carcinoma is a rare malignant endocrine tumor accounting for only 0.5% to 5% of all primary hyperparathyroidism. Among these malignancies, only 10-25% are nonfunctioning. After the review of the literature we could only ascertain a number of 25 cases reported worldwide, since 1929, our case being the 26th, but the first with a very aggressive pathology, treated with chemotherapy scheme usually used for neuroendocrine tumors. Considering these facts, every single case presented is a step forward in defying the clinical presentation, for the awareness of the clinicians, and also in establishing standard adjuvant therapies.


Assuntos
Carboplatina/uso terapêutico , Carcinoma/patologia , Etoposídeo/uso terapêutico , Neoplasias das Paratireoides/patologia , Antineoplásicos/uso terapêutico , Antineoplásicos Fitogênicos/uso terapêutico , Carcinoma/tratamento farmacológico , Carcinoma/cirurgia , Feminino , Humanos , Pessoa de Meia-Idade , Neoplasias das Paratireoides/tratamento farmacológico , Neoplasias das Paratireoides/cirurgia , Paratireoidectomia , Resultado do Tratamento
16.
Ugeskr Laeger ; 174(40): 2392-3, 2012 Oct 01.
Artigo em Dinamarquês | MEDLINE | ID: mdl-23031304

RESUMO

This case report describes a pregnant woman with severe primary hyperparathyroidism. The symptoms, mainly nausea and vomiting, were not recognized as symptoms of hypercalcaemia, but ascribed to the pregnancy. As she was diagnosed, parathyroidectomy was performed and the symptoms ceased. Primary hyperparathyroidism in pregnancy can among other things cause pregnancy loss, intrauterine growth retardation and neonatal tetanus caused by hypocalcaemia. The case demonstrates the need for measuring serum calcium in pregnant women with severe hyper emesis and a record of unexplained miscarriages.


Assuntos
Adenoma/diagnóstico por imagem , Hiperparatireoidismo Primário/diagnóstico , Neoplasias das Paratireoides/diagnóstico por imagem , Adenoma/complicações , Adenoma/tratamento farmacológico , Adenoma/cirurgia , Adulto , Cálcio/sangue , Cálcio/uso terapêutico , Diagnóstico Diferencial , Feminino , Humanos , Hiperparatireoidismo Primário/complicações , Hiperparatireoidismo Primário/tratamento farmacológico , Hiperparatireoidismo Primário/cirurgia , Hormônio Paratireóideo/sangue , Neoplasias das Paratireoides/complicações , Neoplasias das Paratireoides/tratamento farmacológico , Neoplasias das Paratireoides/cirurgia , Pré-Eclâmpsia/etiologia , Gravidez , Complicações Neoplásicas na Gravidez/diagnóstico por imagem , Complicações Neoplásicas na Gravidez/tratamento farmacológico , Complicações Neoplásicas na Gravidez/cirurgia , Resultado do Tratamento , Ultrassonografia
17.
PLoS One ; 7(5): e36448, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22606260

RESUMO

BACKGROUND: Primary hyperparathyroidism (PHPT) is an endocrine disorder most commonly affecting women, suggesting a role for female hormones and/or their receptors in parathyroid adenomas. We here investigated the prolactin receptor (PRLr) which is associated with tumours of the breast and other organs. METHODOLOGY/PRINCIPAL FINDINGS: PRLr expression was investigated in a panel of 37 patients with sporadic parathyroid tumours and its functionality in cultured parathyroid tumour cells. In comparison with other tissues and breast cancer cells, high levels of prolactin receptor gene (PRLR) transcripts were demonstrated in parathyroid tissues. PRLr products of 60/70 kDa were highly expressed in all parathyroid tumours. In addition varying levels of the 80 kDa PRLr isoform, with known proliferative activity, were demonstrated. In parathyroid tumours, PRLr immunoreactivity was observed in the cytoplasm (in all cases, n = 36), cytoplasmic granulae (n = 16), the plasma membrane (n = 12) or enlarged lysosomes (n = 4). In normal parathyroid rim (n = 28), PRLr was uniformly expressed in the cytoplasm and granulae. In in vitro studies of short-term cultured human parathyroid tumour cells, prolactin stimulation was associated with significant transcriptional changes in JAK/STAT, RIG-I like receptor and type II interferon signalling pathways as documented by gene expression profiling. Moreover, PRLR gene expression in parathyroid tumours was inversely correlated with the patients' plasma calcium levels. CONCLUSIONS: We demonstrate that the prolactin receptor is highly abundant in human parathyroid tissues and that PRLr isoforms expression and PRLr subcellular localisation are altered in parathyroid tumours. Responsiveness of PRLr to physiological levels of prolactin was observed in the form of increased PTH secretion and altered gene transcription with significant increase of RIG-I like receptor, JAK-STAT and Type II interferon signalling pathways. These data suggest a role of the prolactin receptor in parathyroid adenomas.


Assuntos
Hiperparatireoidismo Primário/metabolismo , Receptores da Prolactina/metabolismo , Adenoma/tratamento farmacológico , Adenoma/genética , Adenoma/metabolismo , Adulto , Idoso , Idoso de 80 Anos ou mais , Sequência de Bases , Neoplasias da Mama/genética , Neoplasias da Mama/metabolismo , Sinalização do Cálcio/efeitos dos fármacos , Feminino , Expressão Gênica/efeitos dos fármacos , Quinase 3 da Glicogênio Sintase/genética , Quinase 3 da Glicogênio Sintase/metabolismo , Glicogênio Sintase Quinase 3 beta , Humanos , Hiperparatireoidismo Primário/genética , Masculino , Pessoa de Meia-Idade , Glândulas Paratireoides/metabolismo , Hormônio Paratireóideo/metabolismo , Neoplasias das Paratireoides/tratamento farmacológico , Neoplasias das Paratireoides/genética , Neoplasias das Paratireoides/metabolismo , Prolactina/uso terapêutico , Isoformas de Proteínas/genética , Isoformas de Proteínas/metabolismo , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , RNA Neoplásico/genética , RNA Neoplásico/metabolismo , Receptores da Prolactina/genética , Frações Subcelulares/metabolismo
18.
Eur J Endocrinol ; 167(2): 157-64, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22577108

RESUMO

OBJECTIVE: Primary hyperparathyroidism (PHPT) is a challenging problem in type 1 multiple endocrine neoplasia (MEN1) due to the high postsurgery recurrence rate. The aim was to evaluate the efficacy of cinacalcet in MEN1 patients in comparison with patients with sporadic PHPT (sPHPT) and the effect of Arg990Gly calcium-sensing receptor (CASR) polymorphism on the response to treatment. DESIGN: This is a randomized, crossover, double-blind study carried out in the University Hospitals. METHODS: Fifteen MEN1 patients with PHPT were randomized to two groups, one administered with 30 mg daily cinacalcet, titrated until calcium normalization, and one with placebo. After 3 months, patients were reassessed and after washout switched to the other treatment. For comparison, 20 sPHPT patients with similar calcium levels were administered with cinacalcet for 3 months. Ionized and total calcium, phosphate, and parathyroid hormone (PTH) were evaluated. CASR Arg990Gly was genotyped on blood DNA by direct sequencing. RESULTS: Cinacalcet normalized calcium, increased phosphate, and reduced PTH levels in all patients. Cinacalcet dosage required to normalize calcium in MEN1 and sPHPT was not significantly different (45±21 vs 54±25 mg/day). Few mild adverse events, not requiring drug withdrawal, were observed in both the groups. No association between Arg990Gly CASR polymorphism and response to cinacalcet was found. CONCLUSIONS: This short-term prospective study demonstrated that the efficacy profile of cinacalcet in patients with MEN1-related PHPT and in those with sPHPT was similar and was not influenced by the 990 CASR variant. Although long-term safety and efficacy data are required, cinacalcet might be considered a treatment option in MEN1 patients who have contraindications to surgery or persistent PHPT after surgery.


Assuntos
Adenoma/tratamento farmacológico , Hiperparatireoidismo Primário/tratamento farmacológico , Neoplasia Endócrina Múltipla Tipo 1/tratamento farmacológico , Naftalenos/uso terapêutico , Neoplasias das Paratireoides/tratamento farmacológico , Receptores de Detecção de Cálcio/genética , Adenoma/complicações , Adenoma/diagnóstico , Adenoma/genética , Adulto , Substituição de Aminoácidos/genética , Substituição de Aminoácidos/fisiologia , Arginina/genética , Calcimiméticos/uso terapêutico , Cinacalcete , Estudos Cross-Over , Método Duplo-Cego , Feminino , Glicina/genética , Humanos , Hiperparatireoidismo Primário/diagnóstico , Hiperparatireoidismo Primário/etiologia , Hiperparatireoidismo Primário/genética , Masculino , Pessoa de Meia-Idade , Neoplasia Endócrina Múltipla Tipo 1/complicações , Neoplasia Endócrina Múltipla Tipo 1/diagnóstico , Neoplasia Endócrina Múltipla Tipo 1/genética , Neoplasias das Paratireoides/complicações , Neoplasias das Paratireoides/diagnóstico , Neoplasias das Paratireoides/genética , Polimorfismo de Nucleotídeo Único/fisiologia , Prognóstico , Resultado do Tratamento , Adulto Jovem
19.
Ann Endocrinol (Paris) ; 73(3): 225-9, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-22520146

RESUMO

We report here a rare case of a young male patient presenting with a Multiple Endocrine Neoplasia Type 1 - prolactin-secreting pituitary carcinoma, controlled long-term after temozolomide withdrawal. Initial presentation was pituitary apoplexy leading to surgery. Dopamine agonists and radiotherapy allowed control of prolactin secretion and pituitary remnant. Metastasis appeared 10 years after initial presentation, leading to the diagnosis of pituitary carcinoma. At that time, dopamine agonists were no more effective; temozolomide, an oral alkylating agent, was administered for 24 cycles, and allowed decrease of the volume of the pituitary lesion and metastases. The patient is still currently followed in our department, 3 years after temozolomide withdrawal: prolactin level and pituitary tumor volume remain controlled without any chemotherapy. To our knowledge, this is the first case of MEN1 prolactin secreting pituitary carcinoma controlled long-term after temozolomide discontinuation.


Assuntos
Antineoplásicos/uso terapêutico , Carcinoma/tratamento farmacológico , Dacarbazina/análogos & derivados , Neoplasia Endócrina Múltipla Tipo 1/tratamento farmacológico , Recidiva Local de Neoplasia/tratamento farmacológico , Neoplasias Hipofisárias/tratamento farmacológico , Adulto , Carcinoma/complicações , Carcinoma/genética , Carcinoma/metabolismo , Carcinoma/radioterapia , Carcinoma/cirurgia , Terapia Combinada , Irradiação Craniana , Dacarbazina/uso terapêutico , Agonistas de Dopamina/uso terapêutico , Terapia de Reposição Hormonal , Humanos , Hiperprolactinemia/tratamento farmacológico , Hiperprolactinemia/etiologia , Hipofisectomia/efeitos adversos , Hipopituitarismo/tratamento farmacológico , Hipopituitarismo/etiologia , Masculino , Mutação de Sentido Incorreto , Oftalmoplegia/etiologia , Neoplasias Pancreáticas/diagnóstico , Neoplasias Pancreáticas/tratamento farmacológico , Neoplasias Pancreáticas/genética , Neoplasias das Paratireoides/diagnóstico , Neoplasias das Paratireoides/tratamento farmacológico , Neoplasias das Paratireoides/genética , Apoplexia Hipofisária/etiologia , Neoplasias Hipofisárias/complicações , Neoplasias Hipofisárias/genética , Neoplasias Hipofisárias/metabolismo , Neoplasias Hipofisárias/radioterapia , Neoplasias Hipofisárias/cirurgia , Prolactina/metabolismo , Proteínas Proto-Oncogênicas/genética , Radioterapia Adjuvante , Indução de Remissão , Neoplasias da Coluna Vertebral/diagnóstico , Neoplasias da Coluna Vertebral/tratamento farmacológico , Neoplasias da Coluna Vertebral/genética , Temozolomida
20.
J Endocrinol ; 210(1): 105-15, 2011 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-21478229

RESUMO

Statins show antiproliferative activity in various cancer cells. The aim of this study was to evaluate the effects of rosuvastatin treatment on papillary thyroid carcinoma. The papillary thyroid carcinoma (B-CPAP) and normal (Nthy-ori 3-1) thyroid cell lines were treated with rosuvastatin at 12.5, 18.5, 25, 50, 100, and 200 µM concentrations. After 48 and 72 h of rosuvastatin treatment, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide, Ki-67 immunolabeling, FACS analysis, electron microscopy, caspase-3, and terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) analysis were performed. Decreased cell viability and G1 phase arrest were detected in papillary thyroid cell line treated with rosuvastatin. Positive immunoreactivity of Ki-67 and dose-dependent increase in S phase on Nthy-ori 3-1 cells were also detected. B-CPAP cells showed intense vacuolisation and autophagosomes with low concentrations and 48 h incubations, while Nthy-ori 3-1 cells showed these changes at higher concentrations. A decrease in the percentage of cells showing autophagy was determined with increasing concentrations of rosuvastatin in B-CPAP cells. Rosuvastatin treatment also caused a dose- and time-dependent increase in caspase-3 activity and apoptotic index by TUNEL assay in B-CPAP cells compared with the Nthy-ori 3-1 cells. Apoptotic cells with nuclear condensation and fragmentation were observed in B-CPAP cell line. Rosuvastatin induced autophagic changes in B-CPAP papillary thyroid cancer cells in lower doses and caused a shift from autophagy to apoptosis. Rosuvastatin may be an alternative treatment for refractory papillary thyroid cancer. Further in vivo studies are necessary to clarify the effects of rosuvastatin in papillary thyroid carcinoma and the clinical implications of rosuvastatin treatment.


Assuntos
Antineoplásicos/farmacologia , Apoptose/efeitos dos fármacos , Carcinoma Papilar/tratamento farmacológico , Fluorbenzenos/farmacologia , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia , Neoplasias das Paratireoides/tratamento farmacológico , Pirimidinas/farmacologia , Sulfonamidas/farmacologia , Autofagia/efeitos dos fármacos , Carcinoma Papilar/metabolismo , Carcinoma Papilar/ultraestrutura , Caspase 3/metabolismo , Linhagem Celular Tumoral , Núcleo Celular/efeitos dos fármacos , Núcleo Celular/ultraestrutura , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Fase G1/efeitos dos fármacos , Humanos , Marcação In Situ das Extremidades Cortadas , Antígeno Ki-67/metabolismo , Microscopia Eletrônica de Transmissão , Concentração Osmolar , Neoplasias das Paratireoides/metabolismo , Neoplasias das Paratireoides/ultraestrutura , Rosuvastatina Cálcica , Fatores de Tempo , Vacúolos/efeitos dos fármacos , Vacúolos/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...